白细胞介素-33及其受体ST2在小儿炎性肠病中的免疫调节作用

Immunomodulatory effects of interleukin-33 and corresponding receptor ST2 on children with inflammatory bowel disease

目的研究白细胞介素(IL)-33及其受体ST2介导的细胞因子在小儿炎性肠病中的变化,探索IL-33及其受体ST2在小儿炎性肠病中的免疫调节作用。方法将44例患儿分为溃疡性结肠炎(UC)组和克罗恩病(CD)组,比较两组患儿治疗前后外周血中IL-33、IL-4、IL-6、IL-5、IL-13、γ-干扰素(INF-γ)、肿瘤坏死因子-α(TNF-α)的变化。结果治疗前两组患儿IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α比较差异无显著性(P>0.05);治疗后两组患儿IL-33、IL-5、IL-13较治疗前显著降低(P<0.05),IL-6、INF-γ、TNF-α较治疗前显著升高(P<0.05);治疗后两组患儿IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α比较差异无显著性(P>0.05)。结论炎性肠病患儿肠道组织中浸润的巨噬细胞是IL-33的主要来源,IL-33的增加会使Th2型细胞因子(IL-5、IL-13)明显增加,而Th1型细胞因子(INF-γ、IL-6、TNF-α)明显减少。IL-33可有效缓解炎性肠病的进展。

Objective To study on changes in interleukin（IL）-33 and cell factors of its receptor mediated by ST2 in children within flammatory bowel disease and to explore immune regulatory effects of IL-33 and its receptor ST2 on children with inflammatory bowel disease. Method 44 patients were divided into ulcerative colitis（UC） group and Crohn＇s disease（CD） group, the changes in IL-33 peripheral blood and IL-4, IL-6, IL-5, IL-13 and gamma-interferon（INF-γ） and tumor necrosis factor alpha（TNF-α） of patients in two groups before and after treatment were compared. Result The comparisons in IL-33, IL-4, IL-6, IL-5, IL-13, INF-γ and TNF-α were no significantly different before treatment（P〉0.05）, the levels of IL-33, IL-5 and IL-13 of patients in two groups were significantly lower when compared to those after treatment（P〈0.05）, and the levels of IL-6, INF-γ and TNF-α of patients in two groups were significantly increased when compared to those after treatment（P〈0.05）, and the comparisons in IL-33, IL-4, IL-6, IL-5, IL-13, INF-γ and TNF-α were not significantly different（P〉0.05）. Conclusion Macrophages infiltrating in intestinal tissues of patients with inflammatory bowel disease are main sources of IL-33, the rise in the quantity of IL-33 will significantly increase the quantity of Th2-type cytokines（IL-5, IL-13）, while the number of Th1-type cell factors（INF-γ, IL-6, TNF-α） will significantly reduced. IL-33 is capable of effectively alleviating the progress of inflammatory bowel disease.